about
BRAF mutations in hairy-cell leukemiaHepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphomaIncreased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutationBlast phase of essential thrombocythemia: A single center study.Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia.Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.Everolimus in diffuse large B-cell lymphomas.A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection.The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.The genetics of nodal marginal zone lymphomaPrimary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease.Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana LinfomiB-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins.Mycosis fungoides: disease evolution of the "lion queen" revisited.Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphoInvestigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.Splenic marginal zone lymphoma: from genetics to management.Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Antiviral therapies for managing viral hepatitis in lymphoma patients.Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas.Novel agents in indolent lymphomas.A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma.The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis.Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.Splenic marginal zone lymphoma: hydra with many heads?Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection.
P50
Q24609980-D0AA7893-59B2-46D7-946D-A099D34C2805Q26750997-DBBC45FF-F2F5-489F-A516-3936C39021C9Q27851655-9536D921-6100-451B-ACAF-83414F14033BQ27851888-296C4F1B-77AD-421A-A95B-9E4C25A4A84EQ28080160-E4D1840A-13C4-42AF-BD16-41BF0F3F9456Q28222209-2B2E3C9C-EF42-459E-A6C3-7E0C768E0C1DQ33385885-31812915-FC05-445C-BC81-60AFA176DDFDQ33386154-8B13F895-9A14-4383-97B1-AD52F1628ED4Q33414243-A43BD843-DF00-411F-852D-011653D0A724Q33420346-D187883D-C153-411F-A1C6-E81DC8EB64DDQ33425935-A252A167-DC97-409C-AD1F-3D0D8C4669A8Q33617237-8593720D-FBCD-4A68-B243-422E38FA034CQ33963986-10E53592-3CE9-4F88-A69A-1A1B9B3B6399Q34252178-7A04923E-C18F-4666-802C-14EB62EFAA5BQ35236063-F6DC16D9-CB39-4602-918C-34F403172AFFQ35561291-1044D62D-71D2-4F0D-9FF0-C386C6645502Q36204525-F034E193-A508-443D-9408-A2F333749DD1Q36715896-39051FD8-EBD6-4B46-84CF-5072D3D956DAQ37243257-12087E81-EA92-409E-AAE7-CCF84FAE564AQ37373066-7A5D1591-5CC7-4F04-9068-C97622A9DA1AQ37528530-55B6D490-D3E3-44A0-B06B-20FDDA284890Q37618904-41C66041-A4C6-47BC-A3D7-C544B852FDC7Q37623529-A82A9AB3-B40D-4084-8ED3-8F61096E904BQ38059605-7E6E80A0-9167-4060-800D-B0AAF35627C2Q38238460-2EEF6337-276E-4923-820D-971EBA6AA463Q38434473-F6F1D589-D4FF-4D3C-8B8B-1097F350A609Q38779321-8A9802AB-C5FF-438F-A5DE-A225DFDEB50AQ38878808-3B448673-D081-4676-A8C3-C2F0FC465796Q38878814-0CFFF23B-E1F9-4141-BA8F-E08EE3D8068AQ38896683-4BCE89DE-CD24-44F2-90F2-4B0B268E466BQ38989625-B9107071-C131-48D9-892C-18A5AB87D2F1Q39246289-98E8A546-D73B-4454-98AB-965358258564Q39431412-CEEDFEAF-F4EB-4FA3-AC61-D016304E062AQ40573378-27FED5BB-A039-45AF-BE9D-3D04D5A7EB7BQ40774061-23D4A092-8B44-44FE-9185-71923170ED08Q40892006-44D1F370-D08A-4590-A94F-9FE02FB4F6D0Q41696221-57CBCD1A-A13F-47B9-98A6-2352277E4CBCQ42639007-F5B45F39-0641-45C4-B955-005D47AFD280Q42832521-DB8F133D-0B1C-42B3-A937-C285ABBAC312Q42984351-130399A9-28B5-47DC-81DB-AC8BCA95FCCA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Luca Arcaini
@ast
Luca Arcaini
@en
Luca Arcaini
@es
Luca Arcaini
@nl
Luca Arcaini
@sl
type
label
Luca Arcaini
@ast
Luca Arcaini
@en
Luca Arcaini
@es
Luca Arcaini
@nl
Luca Arcaini
@sl
prefLabel
Luca Arcaini
@ast
Luca Arcaini
@en
Luca Arcaini
@es
Luca Arcaini
@nl
Luca Arcaini
@sl
P1053
P-8913-2015
P106
P21
P31
P3829
P496
0000-0002-9504-991X